NCT03522298View on ClinicalTrials.gov

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Glioblastoma, Adult
Interventions
DRUG

Paxalisib (GDC-0084)

Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.

Trial Locations (6)

73104

University of Oklahoma Health Sciences Center (Stephenson Cancer Center), Oklahoma City

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

90095

University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles

02115

Dana Farber Cancer Institute, Boston

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Kazia Therapeutics Limited

INDUSTRY

NCT03522298 - Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma | Biotech Hunter | Biotech Hunter